NO20080801L - Aerosolformulering for inhalering av beta-agonister - Google Patents
Aerosolformulering for inhalering av beta-agonisterInfo
- Publication number
- NO20080801L NO20080801L NO20080801A NO20080801A NO20080801L NO 20080801 L NO20080801 L NO 20080801L NO 20080801 A NO20080801 A NO 20080801A NO 20080801 A NO20080801 A NO 20080801A NO 20080801 L NO20080801 L NO 20080801L
- Authority
- NO
- Norway
- Prior art keywords
- inhalation
- aerosol formulation
- beta agonists
- formula
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Oppfinnelsen angår en aerosolformulering for. inhalering, som er uten drivmiddel og som inneholder én eller flere forbindelser med den generelle formel (1) og et ytterligere virkestoff (2). I den nevnte formel kan gruppene R, R, Rog XT være definert som omtalt i kravene og beskrivelsen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05109376 | 2005-10-10 | ||
PCT/EP2006/067126 WO2007042468A2 (de) | 2005-10-10 | 2006-10-06 | Aerosolformulierung für die inhalation von betaagonisten |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20080801L true NO20080801L (no) | 2008-04-29 |
NO343363B1 NO343363B1 (no) | 2019-02-11 |
Family
ID=35241312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080801A NO343363B1 (no) | 2005-10-10 | 2008-02-14 | Medikamentformulering, anvendelse av medikamentformuleringen for fremstilling av et farmasøytisk preparat for behandling av respiratoriske sykdommer og inhalasjonssett inneholdende samme |
Country Status (31)
Country | Link |
---|---|
US (3) | US20070088030A1 (no) |
EP (1) | EP1940349B1 (no) |
JP (1) | JP2009511542A (no) |
KR (1) | KR20080059290A (no) |
CN (1) | CN101282712A (no) |
AR (1) | AR058082A1 (no) |
AU (1) | AU2006301330B9 (no) |
BR (1) | BRPI0617278A2 (no) |
CA (1) | CA2624786C (no) |
CY (1) | CY1120199T1 (no) |
DK (1) | DK1940349T3 (no) |
EA (1) | EA200800927A1 (no) |
EC (1) | ECSP088294A (no) |
ES (1) | ES2668364T3 (no) |
HR (1) | HRP20180713T1 (no) |
HU (1) | HUE039186T2 (no) |
IL (1) | IL190682A (no) |
LT (1) | LT1940349T (no) |
MY (1) | MY163503A (no) |
NO (1) | NO343363B1 (no) |
NZ (1) | NZ567545A (no) |
PE (1) | PE20070708A1 (no) |
PL (1) | PL1940349T3 (no) |
PT (1) | PT1940349T (no) |
RS (1) | RS57085B1 (no) |
SI (1) | SI1940349T1 (no) |
TW (1) | TWI389692B (no) |
UA (1) | UA99250C2 (no) |
UY (1) | UY29844A1 (no) |
WO (1) | WO2007042468A2 (no) |
ZA (1) | ZA200801390B (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
KR101360803B1 (ko) * | 2005-08-15 | 2014-02-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타모방제의 제조방법 |
CA2738616A1 (en) * | 2008-11-21 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta agonists |
JP2012509299A (ja) * | 2008-11-21 | 2012-04-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | β作用薬吸入用のエアロゾル製剤 |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
JP2015533131A (ja) * | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 咳を治療するためのベータ2−アドレナリン受容体作動薬 |
US20140235627A1 (en) * | 2012-12-21 | 2014-08-21 | Boehringer Ingelheim International Gmbh | ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
CA2986839C (en) * | 2015-05-18 | 2021-06-15 | Glenmark Specialty S.A. | Tiotropium inhalation solution for nebulization |
JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
US20210322311A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol |
CN114259481A (zh) * | 2021-11-26 | 2022-04-01 | 南京华盖制药有限公司 | 一种奥达特罗复方吸入溶液 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
SK280911B6 (sk) * | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostriedok |
CZ20023537A3 (cs) * | 2000-04-27 | 2003-02-12 | Boehringer Ingelheim Pharma Kg | Betamimetika, způsob jejich výroby a použití jako farmaceutický prostředek |
DE10216036A1 (de) | 2002-04-11 | 2003-10-23 | Boehringer Ingelheim Pharma | Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz |
DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7244728B2 (en) * | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
KR101287460B1 (ko) * | 2004-04-22 | 2013-07-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물 |
US20050239778A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
US7220742B2 (en) * | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
-
2006
- 2006-10-05 US US11/543,477 patent/US20070088030A1/en not_active Abandoned
- 2006-10-05 TW TW095137046A patent/TWI389692B/zh active
- 2006-10-06 MY MYPI20081057A patent/MY163503A/en unknown
- 2006-10-06 CA CA2624786A patent/CA2624786C/en not_active Expired - Fee Related
- 2006-10-06 HU HUE06807028A patent/HUE039186T2/hu unknown
- 2006-10-06 KR KR1020087011009A patent/KR20080059290A/ko not_active Application Discontinuation
- 2006-10-06 CN CNA2006800377251A patent/CN101282712A/zh active Pending
- 2006-10-06 WO PCT/EP2006/067126 patent/WO2007042468A2/de active Application Filing
- 2006-10-06 DK DK06807028.3T patent/DK1940349T3/en active
- 2006-10-06 UY UY29844A patent/UY29844A1/es not_active Application Discontinuation
- 2006-10-06 EP EP06807028.3A patent/EP1940349B1/de active Active
- 2006-10-06 NZ NZ567545A patent/NZ567545A/en unknown
- 2006-10-06 PT PT68070283T patent/PT1940349T/pt unknown
- 2006-10-06 ES ES06807028.3T patent/ES2668364T3/es active Active
- 2006-10-06 EA EA200800927A patent/EA200800927A1/ru unknown
- 2006-10-06 RS RS20180434A patent/RS57085B1/sr unknown
- 2006-10-06 SI SI200632255T patent/SI1940349T1/en unknown
- 2006-10-06 PL PL06807028T patent/PL1940349T3/pl unknown
- 2006-10-06 JP JP2008535001A patent/JP2009511542A/ja active Pending
- 2006-10-06 AU AU2006301330A patent/AU2006301330B9/en active Active
- 2006-10-06 BR BRPI0617278-4A patent/BRPI0617278A2/pt not_active Application Discontinuation
- 2006-10-06 AR ARP060104405A patent/AR058082A1/es not_active Application Discontinuation
- 2006-10-06 LT LTEP06807028.3T patent/LT1940349T/lt unknown
- 2006-10-06 UA UAA200805249A patent/UA99250C2/ru unknown
- 2006-10-06 PE PE2006001218A patent/PE20070708A1/es not_active Application Discontinuation
-
2008
- 2008-02-11 ZA ZA200801390A patent/ZA200801390B/xx unknown
- 2008-02-14 NO NO20080801A patent/NO343363B1/no unknown
- 2008-03-19 EC EC2008008294A patent/ECSP088294A/es unknown
- 2008-04-08 IL IL190682A patent/IL190682A/en active IP Right Grant
-
2009
- 2009-09-22 US US12/564,477 patent/US20100009984A1/en not_active Abandoned
-
2011
- 2011-04-14 US US13/087,009 patent/US20110190284A1/en not_active Abandoned
-
2018
- 2018-05-07 HR HRP20180713TT patent/HRP20180713T1/hr unknown
- 2018-05-10 CY CY20181100484T patent/CY1120199T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080801L (no) | Aerosolformulering for inhalering av beta-agonister | |
NO20090410L (no) | Aerosolformuleringer for inhalaering av beta-agonister | |
NO20090407L (no) | Aerosolformulering for inhalering av beta agonister | |
NO20050828L (no) | lndol-3-svovelderivater | |
NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
WO2008009379A3 (de) | Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
WO2009082152A3 (en) | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
MX2009004746A (es) | Derivados de 1,2,4-triazol como inhibidores del receptor sigma. | |
NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
WO2007125103A3 (en) | Benzamide glucokinase activators | |
EP2023724B8 (de) | Synergistische wirkstoffkombinationen | |
NO20082496L (no) | Pyrazinderivater | |
TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
NZ592429A (en) | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
HK1120794A1 (en) | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | |
NO20065030L (no) | Aerosolformulering for inhalering av beta agonister. | |
NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
NO20080110L (no) | Benzimidazolderivativer som 5-HT6,5-HT24 | |
WO2006031929A3 (en) | Thiazolopyridine kinase inhibitors | |
WO2006110173A3 (en) | Novel compounds | |
WO2004067703A3 (en) | 5ht7 antagonists and inverse agonists | |
NO20076396L (no) | Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette |